The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy.

PubWeight™: 1.09‹?› | Rank: Top 10%

🔗 View Article (PMID 14758508)

Published in Cancer Immunol Immunother on January 31, 2004

Authors

Harpreet Singh-Jasuja1, Niels P N Emmerich, Hans-Georg Rammensee

Author Affiliations

1: Department of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.

Articles citing this

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44

Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood (2006) 2.11

The MHC class I peptide repertoire is molded by the transcriptome. J Exp Med (2008) 1.31

Sequence analysis of T-cell repertoires in health and disease. Genome Med (2013) 1.17

Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics (2015) 1.08

A mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines. PLoS Comput Biol (2008) 1.06

HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines (2013) 0.94

Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89

The messenger and the message: gp96 (GRP94)-peptide interactions in cellular immunity. Cell Stress Chaperones (2004) 0.89

Cancer vaccines: Looking to the future. Oncoimmunology (2013) 0.88

A quest for therapeutic antigens in bone and soft tissue sarcoma. J Transl Med (2005) 0.85

Immunology of hepatocellular carcinoma. World J Hepatol (2015) 0.83

Higher throughput methods of identifying T cell epitopes for studying outcomes of altered antigen processing and presentation. Front Immunol (2013) 0.81

Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine (2009) 0.81

Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma. Br J Haematol (2013) 0.77

New clinical advances in immunotherapy for the treatment of solid tumours. Immunology (2015) 0.76

Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells. Front Oncol (2014) 0.75

Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines (Basel) (2015) 0.75

Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy. PLoS One (2016) 0.75

Multi-peptide immunotherapeutic vaccine for renal cell carcinoma: getting the troops all worked up. Transl Androl Urol (2012) 0.75

Articles by these authors

(truncated to the top 100)

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44

Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A (2005) 3.75

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood (2002) 2.88

Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol (2002) 2.72

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood (2003) 2.50

The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem (2002) 2.39

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26

Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques (2003) 1.95

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother (2008) 1.88

Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol (2005) 1.85

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A (2002) 1.85

CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood (2009) 1.79

Neurological symptoms in patients with biopsy proven celiac disease. Mov Disord (2009) 1.69

Characterizing the N-terminal processing motif of MHC class I ligands. J Immunol (2008) 1.68

Tumor-associated MICA is shed by ADAM proteases. Cancer Res (2008) 1.64

Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. J Immunol (2004) 1.63

MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res (2003) 1.60

More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol (2011) 1.56

Primary blood neutrophils express a functional cell surface Toll-like receptor 9. Eur J Immunol (2013) 1.52

Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood (2007) 1.48

Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol (2003) 1.46

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. 1991. J Immunol (2006) 1.45

Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother (2009) 1.44

Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) (2006) 1.40

Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother (2008) 1.40

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32

MAPPP: MHC class I antigenic peptide processing prediction. Appl Bioinformatics (2003) 1.31

Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res (2002) 1.28

Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics (2006) 1.26

Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem (2006) 1.26

Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. Blood (2012) 1.23

Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res (2002) 1.23

Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol (2008) 1.20

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate (2009) 1.20

Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19

Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons. Nat Commun (2013) 1.18

Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat Biotechnol (2004) 1.13

Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J (2007) 1.11

Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res (2011) 1.10

Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol (2006) 1.09

HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother (2009) 1.08

Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J Immunol (2005) 1.08

Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur J Immunol (2008) 1.08

Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett (2007) 1.07

Evidence for shared recognition of a peptide ligand by a diverse panel of non-obese diabetic mice-derived, islet-specific, diabetogenic T cell clones. Int Immunol (2002) 1.06

Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest (2007) 1.05

Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol (2005) 1.05

Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood (2002) 1.05

Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J Immunol (2004) 1.04

The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood (2002) 1.03

Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother (2004) 1.03

Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res (2006) 1.02

Characterization of the ribonuclease activity on the skin surface. Genet Vaccines Ther (2006) 1.01

The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering. Immunobiology (2012) 1.01

Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer (2011) 1.00

Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br J Haematol (2002) 1.00

Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype. Eur J Immunol (2008) 0.99

Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc Natl Acad Sci U S A (2006) 0.99

Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res (2007) 0.99

Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res (2004) 0.98

High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur J Immunol (2005) 0.98

Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol (2002) 0.97

Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol (2004) 0.97

Human platelets express heat shock protein receptors and regulate dendritic cell maturation. Blood (2002) 0.96

Dendritic cell aggresome-like-induced structure formation and delayed antigen presentation coincide in influenza virus-infected dendritic cells. J Immunol (2005) 0.95

A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol (2003) 0.95

Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres. J Immunol (2003) 0.95

The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol (2013) 0.94

Effective chemokine secretion by dendritic cells and expansion of cross-presenting CD4-/CD8+ dendritic cells define a protective phenotype in the mouse model of coxsackievirus myocarditis. J Virol (2008) 0.94

Glycan side chains on naturally presented MHC class II ligands. J Mass Spectrom (2005) 0.94

Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother (2006) 0.93

Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling. J Immunol (2008) 0.93

TLR2/TLR4-independent neutrophil activation and recruitment upon endocytosis of nucleosomes reveals a new pathway of innate immunity in systemic lupus erythematosus. J Immunol (2006) 0.93

NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood (2008) 0.93

Toll-like receptors 2 and 4 impair insulin-mediated brain activity by interleukin-6 and osteopontin and alter sleep architecture. FASEB J (2012) 0.93

Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. J Proteome Res (2009) 0.92

EpiToolKit--a web server for computational immunomics. Nucleic Acids Res (2008) 0.91

Quantitative analysis of mouse urine volatiles: in search of MHC-dependent differences. PLoS One (2007) 0.91

Identification of Chlamydia pneumoniae-derived mouse CD8 epitopes. Infect Immun (2002) 0.91

Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: implications for systemic lupus erythematosus. Eur J Immunol (2011) 0.91

Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother (2007) 0.91

The repertoire of human tumor-associated epitopes--identification and selection of antigens and their application in clinical trials. Curr Opin Immunol (2013) 0.90

SNEP: SNP-derived epitope prediction program for minor H antigens. Immunogenetics (2005) 0.90

T cell avidity determines the level of CTL activation. Eur J Immunol (2004) 0.90

A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays. Cancer Res (2008) 0.89

Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer (2002) 0.89

Phagocytosis of dying tumor cells by human peritoneal mesothelial cells. J Cell Sci (2011) 0.89

Glycoprotein 96-activated dendritic cells induce a CD8-biased T cell response. Cell Stress Chaperones (2005) 0.89

Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res (2004) 0.89

Human CD4+ T cells displaying viral epitopes elicit a functional virus-specific memory CD8+ T cell response. J Immunol (2007) 0.88

CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors. Cancer Immunol Immunother (2004) 0.87

Comparative analysis of volatile constituents from mice and their urine. J Chem Ecol (2006) 0.87

Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin Cancer Res (2008) 0.87

Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol Immunother (2004) 0.86

Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res (2006) 0.86

Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clin Immunol (2009) 0.86

Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. PLoS One (2013) 0.86

Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer (2010) 0.86

Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer. Cancer Immunol Immunother (2013) 0.85